FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009098155> ?p ?o ?g. }

• W2009098155 abstract "Infiltration of breast tumors by tumor-infiltrating lymphocytes (TIL) has been associated with sensitivity to anthracycline-based chemotherapy. However, it is unclear whether this is true within the estrogen receptor-alpha (ER)-negative subset of breast tumors that frequently manifest high TIL levels.The association of TIL with short-term and long-term clinical response to anthracycline-based therapy was assessed in two independent ER-negative breast cancer cohorts in which patients were categorized as TIL-high or TIL-low. We defined an eight-gene lymphocyte mRNA expression signature (including CD19, CD3D, CD48, GZMB, LCK, MS4A1, PRF1, and SELL) and used unsupervised hierarchical clustering to examine the association between TIL and short-term response to neoadjuvant chemotherapy in a previously published cohort of ER-negative tumors (n = 113). We also examined the association between TIL and long-term chemotherapeutic efficacy in a second cohort of ER-negative tumors (n = 255) with longer than 6 years of median follow-up by using tissue microarrays and immunohistochemistry (IHC) for detection of CD3, CD8, CD4, CD20, and TIA-1.In patients with ER-negative tumors treated with neoadjuvant anthracycline-based chemotherapy, pathologic complete responses (pCRs) were achieved by 23 (74%) of 31 TIL-high patients and 25 (31%) of 80 TIL-low patients (odds ratio (OR), 6.33; 95% confidence interval (CI), 2.49 to 16.08; P < 0.0001). Multivariate logistic regression with standard clinicopathologic features demonstrated that only tumor size (P = 0.037) and TIL status (P = 0.001) were independent predictors of anthracycline response. In the second cohort, adjuvant anthracycline-based therapy was associated with increased disease-free survival (DFS) only in patients with high levels of intraepithelial CD3+ TIL (P = 0.0023). In contrast, outcomes after CMF treatment (cyclophosphamide, methotrexate, and fluorouracil) showed no association with CD3 status. In both cohorts, cytotoxic T-cells were the primary TIL subtype associated with anthracycline sensitivity. Finally, TIL significantly predicted anthracycline sensitivity for both the Her2-positive and triple-negative tumor phenotypes.ER-negative breast cancers with high levels of TIL have heightened sensitivity to anthracycline-based chemotherapy, as assessed by the immediate response to neoadjuvant therapy and long-term outcome following adjuvant therapy. Investigations of TIL-based predictive tests to identify patients likely to benefit from anthracycline-based treatments are warranted." @default.
• W2009098155 created "2016-06-24" @default.
• W2009098155 creator A5019623844 @default.
• W2009098155 creator A5058837420 @default.
• W2009098155 creator A5066165449 @default.
• W2009098155 creator A5079993805 @default.
• W2009098155 creator A5085897552 @default.
• W2009098155 creator A5091101559 @default.
• W2009098155 date "2011-12-01" @default.
• W2009098155 modified "2023-10-10" @default.
• W2009098155 title "Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer" @default.
• W2009098155 cites W1509384822 @default.
• W2009098155 cites W1518308640 @default.
• W2009098155 cites W1861588860 @default.
• W2009098155 cites W1964072966 @default.
• W2009098155 cites W1965354428 @default.
• W2009098155 cites W1970580356 @default.
• W2009098155 cites W1979379635 @default.
• W2009098155 cites W1993362565 @default.
• W2009098155 cites W1995859582 @default.
• W2009098155 cites W2015835607 @default.
• W2009098155 cites W2016612145 @default.
• W2009098155 cites W2027542837 @default.
• W2009098155 cites W2036704696 @default.
• W2009098155 cites W2038381158 @default.
• W2009098155 cites W2044253211 @default.
• W2009098155 cites W2047902191 @default.
• W2009098155 cites W2050139256 @default.
• W2009098155 cites W2053122486 @default.
• W2009098155 cites W2056893124 @default.
• W2009098155 cites W2057084727 @default.
• W2009098155 cites W2066015501 @default.
• W2009098155 cites W2071793654 @default.
• W2009098155 cites W2075131034 @default.
• W2009098155 cites W2087713415 @default.
• W2009098155 cites W2088160256 @default.
• W2009098155 cites W2089966509 @default.
• W2009098155 cites W2093424661 @default.
• W2009098155 cites W2093773243 @default.
• W2009098155 cites W2109462843 @default.
• W2009098155 cites W2113657892 @default.
• W2009098155 cites W2118126404 @default.
• W2009098155 cites W2124640147 @default.
• W2009098155 cites W2130598050 @default.
• W2009098155 cites W2137049683 @default.
• W2009098155 cites W2138718630 @default.
• W2009098155 cites W2140248757 @default.
• W2009098155 cites W2140633375 @default.
• W2009098155 cites W2142153200 @default.
• W2009098155 cites W2142300779 @default.
• W2009098155 cites W2142486051 @default.
• W2009098155 cites W2150380650 @default.
• W2009098155 cites W2151859419 @default.
• W2009098155 cites W2152794841 @default.
• W2009098155 cites W2157058802 @default.
• W2009098155 cites W2164540420 @default.
• W2009098155 cites W2256024156 @default.
• W2009098155 cites W4211221095 @default.
• W2009098155 doi "https://doi.org/10.1186/bcr3072" @default.
• W2009098155 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3326568" @default.
• W2009098155 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22151962" @default.
• W2009098155 hasPublicationYear "2011" @default.
• W2009098155 type Work @default.
• W2009098155 sameAs 2009098155 @default.
• W2009098155 citedByCount "311" @default.
• W2009098155 countsByYear W20090981552012 @default.
• W2009098155 countsByYear W20090981552013 @default.
• W2009098155 countsByYear W20090981552014 @default.
• W2009098155 countsByYear W20090981552015 @default.
• W2009098155 countsByYear W20090981552016 @default.
• W2009098155 countsByYear W20090981552017 @default.
• W2009098155 countsByYear W20090981552018 @default.
• W2009098155 countsByYear W20090981552019 @default.
• W2009098155 countsByYear W20090981552020 @default.
• W2009098155 countsByYear W20090981552021 @default.
• W2009098155 countsByYear W20090981552022 @default.
• W2009098155 countsByYear W20090981552023 @default.
• W2009098155 crossrefType "journal-article" @default.
• W2009098155 hasAuthorship W2009098155A5019623844 @default.
• W2009098155 hasAuthorship W2009098155A5058837420 @default.
• W2009098155 hasAuthorship W2009098155A5066165449 @default.
• W2009098155 hasAuthorship W2009098155A5079993805 @default.
• W2009098155 hasAuthorship W2009098155A5085897552 @default.
• W2009098155 hasAuthorship W2009098155A5091101559 @default.
• W2009098155 hasBestOaLocation W20090981551 @default.
• W2009098155 hasConcept C121608353 @default.
• W2009098155 hasConcept C126322002 @default.
• W2009098155 hasConcept C143998085 @default.
• W2009098155 hasConcept C156957248 @default.
• W2009098155 hasConcept C193270364 @default.
• W2009098155 hasConcept C2776694085 @default.
• W2009098155 hasConcept C2776802502 @default.
• W2009098155 hasConcept C2777701055 @default.
• W2009098155 hasConcept C2778326572 @default.
• W2009098155 hasConcept C530470458 @default.
• W2009098155 hasConcept C71924100 @default.
• W2009098155 hasConcept C84606932 @default.
• W2009098155 hasConceptScore W2009098155C121608353 @default.
• W2009098155 hasConceptScore W2009098155C126322002 @default.
• W2009098155 hasConceptScore W2009098155C143998085 @default.

• next